Triathlon Total Knee System-Additional Components

K190402 · Stryker Orthopaedics (Aka Howmedica Osteonics Corp.) · JWH · Aug 22, 2019 · Orthopedic

Device Facts

Record IDK190402
Device NameTriathlon Total Knee System-Additional Components
ApplicantStryker Orthopaedics (Aka Howmedica Osteonics Corp.)
Product CodeJWH · Orthopedic
Decision DateAug 22, 2019
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 888.3560
Device ClassClass 2
AttributesTherapeutic

Intended Use

General Total Knee Arthroplasty (TKR) Indications: Painful, disabling joint disease of the knee resulting from: noninflammatory degenerative joint disease (including osteoarthritis, traumatic arthritis, or avascular necrosis), rheumatoid arthritis or post-traumatic arthritis. Post-traumatic loss of knee joint configuration and function. Moderate varus, valgus, or flexion deformity in which the ligamentous structures can be returned to adequate function and stability. Revision of previous unsuccessful knee replacement or other procedure. Fracture of the distal femur and/or proximal tibia that cannot be standard fracture -management techniques. The Triathlon® Tritanium® Total Knee System components are indicated for both uncemented use. The Triathlon® Total Knee System beaded with Per-Apatite components are intended for uncemented use only. The Triathlon® All Polyethylene tibial components are indicated for cemented use only. Additional Indications for Posterior Stabilized (PS) and Total Stabilizer (TS) Components: Ligamentous instability requiring implant bearing surface geometries with increased constraint. Absent or non-functioning posterior cruciate ligament. Severe anteroposterior instability of the knee joint. Additional Indications for Total Stabilizer (TS) Components: Severe instability of the knee secondary to compromised collateral ligament integrity or function. Indications for Bone Augments: Painful, disabling joint disease of the knee secondary to: degenerative arthritis, rheumatoid arthritis, or post-traumatic arthritis, complicated by the presence of bone loss. Salvage of previous unsuccessful total knee replacement or other surgical procedure, accompanied by bone loss. Additional Indications for Cone Augments: Severe degeneration or trauma requiring extensive resection and replacement. Femoral and Tibial bone voids. Metaphyseal reconstruction. The Triathlon TS Cone Augments are intended for cemented or cementless use.

Device Story

Triathlon Total Knee System expansion; adds Size 0 femoral/tibial components, modified PS femoral component, and PSR tibial inserts. Components implanted during total knee arthroplasty; performed by orthopedic surgeons in hospital/surgical settings. Size 0 components accommodate smaller patient anatomy; modified PS box reduces anterior bone removal; PSR insert allows increased internal/external rotation in deep flexion. Device provides structural replacement of knee joint surfaces; restores joint function/stability. Clinical benefit: pain relief and improved mobility for patients with degenerative or traumatic knee conditions.

Clinical Evidence

No clinical data. Substantial equivalence supported by bench testing including fatigue testing of femoral/tibial components (ASTM F1800-12), static shear testing of locking mechanisms, contact area/stress analysis, range of motion analysis, and MR conditional evaluation.

Technological Characteristics

Components include femoral, tibial baseplate, and inserts. Materials consistent with predicate Triathlon system. Sterilization via Ethylene Oxide (EN ISO 11135:2014). MR Conditional. Size 0 components feature reduced dimensions; PS femoral component features reduced intercondylar box; PSR insert designed for increased rotation in deep flexion.

Indications for Use

Indicated for patients with painful, disabling knee joint disease (osteoarthritis, traumatic arthritis, avascular necrosis, rheumatoid arthritis, post-traumatic arthritis), post-traumatic loss of function, moderate varus/valgus/flexion deformity, revision of failed knee replacement, or distal femur/proximal tibia fractures. PS/TS components indicated for ligamentous instability, absent posterior cruciate ligament, or severe anteroposterior instability. Bone/cone augments indicated for bone loss or extensive resection/voids.

Regulatory Classification

Identification

A knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace a knee joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum, and a tibial component or components and a retropatellar resurfacing component made of ultra-high molecular weight polyethylene. This generic type of device is limited to those prostheses intended for use with bone cement (§ 888.3027).

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is in blue and includes the letters "FDA" followed by the words "U.S. FOOD & DRUG ADMINISTRATION". August 22, 2019 Stryker Orthopaedics Margaret Crowe Klippel Senior Principal RA Project Manager 325 Corporate Drive Mahwah, New Jersey 07430 Re: K190402 Trade/Device Name: Triathlon Total Knee System- Additional Components Regulation Number: 21 CFR 888.3565 Regulation Name: Knee Joint Patellofemorotibial Metal/Polymer Porous-Coated Uncemented Prosthesis Regulatory Class: Class II Product Code: MBH, JWH Dated: July 25, 2019 Received: July 29, 2019 Dear Margaret Crowe Klippel: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal {1}------------------------------------------------ statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely. For CAPT Raquel Peat, PhD, MPH, USPHS Director OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ # Indications for Use 510(k) Number (if known) K190402 Device Name Triathlon Total Knee System Indications for Use (Describe) Indications for Use: General Total Knee Arthroplasty (TKR) Indications: · Painful, disabling joint disease of the knee resulting from: noninflammatory degenerative joint disease (including osteoarthritis, traumatic arthritis, or avascular necrosis), rheumatoid arthritis or post-traumatic arthritis. - · Post-traumatic loss of knee joint configuration and function. - · Moderate varus, valgus, or flexion deformity in which the ligamentous structures can be returned to adequate function and stability. - · Revision of previous unsuccessful knee replacement or other procedure. - · Fracture of the distal femur and/or proximal tibia that cannot be standard fracture -management techniques. The Triathlon® Tritanium® Total Knee System components are indicated for both uncemented use. The Triathlon® Total Knee System beaded with Per-Apatite components are intended for uncemented use only. The Triathlon® All Polyethylene tibial components are indicated for cemented use only. Additional Indications for Posterior Stabilized (PS) and Total Stabilizer (TS) Components: - · Ligamentous instability requiring implant bearing surface geometries with increased constraint. - · Absent or non-functioning posterior cruciate ligament. - · Severe anteroposterior instability of the knee joint. Additional Indications for Total Stabilizer (TS) Components: · Severe instability of the knee secondary to compromised collateral ligament integrity or function. #### Indications for Bone Augments: · Painful, disabling joint disease of the knee secondary to: degenerative arthritis, rheumatoid arthritis, or post-traumatic arthritis, complicated by the presence of bone loss. · Salvage of previous unsuccessful total knee replacement or other surgical procedure, accompanied by bone loss. Additional Indications for Cone Augments: - Severe degeneration or trauma requiring extensive resection and replacement - · Femoral and Tibial bone voids - · Metaphyseal reconstruction The Triathlon TS Cone Augments are intended for cemented or cementless use. Type of Use (Select one or both, as applicable) X | Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) {3}------------------------------------------------ ### CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. #### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {4}------------------------------------------------ # Indications for Use 510(k) Number (if known) K190402 Device Name Triathlon Tritanium Tibial Baseplate Indications for Use (Describe) Indications for Use: General Total Knee Arthroplasty (TKR) Indications: · Painful, disabling joint disease of the knee resulting from: non-inflammatory degenerative joint disease (including osteoarthritis, traumatic arthritis or avascular necrosis) rheumatoid arthritis or post-traumatic arthritis - · Post-traumatic loss of knee joint configuration and function - · Moderate varus, valgus, or flexion deformity in which the ligamentous structures can be returned to adequate function and stability - · Revision of previous unsuccessful knee replacement or other procedure - · Fracture of the distal femur and/or proximal tibia that cannot be stabilized by standard fracture management techniques Additional General Total Knee Arthroplasty (TKR) Indications specific to the PS implant: - · Ligamentous instability requiring implant bearing surface geometries with increased constraint - · Absent or non-functioning posterior cruciate ligament - · Severe anteroposterior instability of the knee joint The Triathlon Tritanium Tibial Baseplates are indicated for both cemented and uncemented use. Type of Use (Select one or both, as applicable) | <span style="font-size: 10pt;">☑ Prescription Use (Part 21 CFR 801 Subpart D)</span> | <span style="font-size: 10pt;">☐ Over-The-Counter Use (21 CFR 801 Subpart C)</span> | |--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------| |--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------| #### CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. #### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {5}------------------------------------------------ ### 510(k) Summary | Sponsor | Stryker Orthopaedics<br>325 Corporate Drive<br>Mahwah, NJ 07430 | |----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Contact Person | Margaret Klippel<br>Senior Principal Regulatory Affairs Project Manager<br>Howmedica Osteonics Corp<br>325 Corporate Drive<br>Mahwah, NJ 07430<br>Phone: (201) 831-5559 | | Alternate Contact | Kristen Meany<br>Sr. Manager, Regulatory Affairs<br>Howmedica Osteonics Corp<br>325 Corporate Drive<br>Mahwah, NJ 07430<br>Phone: (201) 972-9164 | | Date Prepared: | February 18, 2019 | | Proprietary Name: | Triathlon® Total Knee System – Additional Components | | Common Name: | Total Knee Joint Replacement | | Classification Name: | Knee joint patellofemorotibial metal/polymer porous-coated<br>uncemented prosthesis. (21 CFR 888.3565)<br>Knee joint patellofemorotibial polymer/metal/polymer semi-<br>constrained cemented prosthesis (21 CFR 888.3560) | | Product Codes: | MBH, IWH | # Legally Marketed Device to Which Substantial Equivalence is Claimed: Triathlon Cruciate Retaining (CR) Femoral Component - K040267, K141056, K172326 Triathlon Posterior Stabilizing (PS) Femoral Component - K042993, K141056, K172326 Triathlon Primary Cemented Tibial Baseplate - K031729, K141056, K172326 Triathlon Tritanium Tibial Baseplate - K123486, K141056, K172326 Triathlon X3 ETO Tibial Inserts (CR, Condylar Stabilizing [CS], and PS) - K172634, K173849 Triathlon N2Vac Tibial Inserts (CR, CS, and PS) – K031729, K040267, K063423, K141056, K172326, K173849 ### Device Description: The additional components being added to the Triathlon Total Knee System are: - Size 0 Cruciate Retaining Femoral Component (cemented use) . {6}------------------------------------------------ - o Size 0 Primary Cemented Tibial Baseplate - Size 0 Tritanium Tibial Baseplate for cemented/cementless use ● - Size 0 CR, CS, and PS Tibial Inserts in X3 ETO and N2Vac ● - New PS Femoral Component with modified intercondylar PS box (cemented use) ● - o New PSR (Posterior Stabilizing Rotation ) tibial insert in sizes 0-8 in X3 ETO Additionally, engineering analyses and finite element analyses were presented to document the range of motion available with the Triathlon Total Knee System. ## Intended Use: The subject Triathlon Femoral components, Primary tibial baseplate, and tibial inserts have the same intended use as those specified in the 510(k) submissions for the predicate devices listed. # Indications: General Total Knee Arthroplasty (TKR) Indications: - Painful, disabling joint disease of the knee resulting from: noninflammatory degenerative . joint disease (including osteoarthritis, traumatic arthritis, or avascular necrosis), rheumatoid arthritis or post-traumatic arthritis. - Post-traumatic loss of knee joint configuration and function. ● - Moderate varus, valgus, or flexion deformity in which the ligamentous structures can be returned to adequate function and stability. - Revision of previous unsuccessful knee replacement or other procedure. ● - o Fracture of the distal femur and/or proximal tibia that cannot be stabilized by standard fracture -management techniques. The Triathlon® Tritanium® Total Knee System components are indicated for both uncemented and cemented use. The Triathlon® Total Knee System beaded and beaded with Peri-Apatite components are intended for uncemented use only. The Triathlon® All Polyethylene tibial components are indicated for cemented use only. Additional Indications for Posterior Stabilized (PS) and Total Stabilizer (TS) Components: - Ligamentous instability requiring implant bearing surface geometries with increased ● constraint. - Absent or non-functioning posterior cruciate ligament. . - Severe anteroposterior instability of the knee joint. 0 Additional Indications for Total Stabilizer (TS) Components: - Severe instability of the knee secondary to compromised collateral ligament integrity or ● function. Indications for Bone Augments: {7}------------------------------------------------ - o Painful, disabling joint disease of the knee secondary to: degenerative arthritis, rheumatoid arthritis, or post-traumatic arthritis, complicated by the presence of bone loss. - 0 Salvage of previous unsuccessful total knee replacement or other surgical procedure. accompanied by bone loss. Additional Indications for Cone Augments: - Severe degeneration or trauma requiring extensive resection and replacement - Femoral and Tibial bone voids - . Metaphyseal reconstruction The Triathlon TS Cone Augment components are intended for cemented or cementless use. The subject Triathlon Tritanium Tibial Baseplate share indications for use as the existing Triathlon Tritanium Tibial Baseplates: General Total Knee Arthroplasty (TKR) Indications: - Painful, disabling joint disease of the knee resulting from: non-inflammatory ● degenerative joint disease (including osteoarthritis, traumatic arthritis or avascular necrosis) rheumatoid arthritis or post-traumatic arthritis - Post-traumatic loss of knee joint configuration and function ● - Moderate varus, valgus, or flexion deformity in which the ligamentous structures can be o returned to adequate function and stability - . Revision of previous unsuccessful knee replacement or other procedure - Fracture of the distal femur and/or proximal tibia that cannot be stabilized by standard ● fracture management techniques Additional General Total Knee Arthroplasty (TKR) Indications specific to the PS implant: - o Ligamentous instability requiring implant bearing surface geometries with increased constraint - Absent or non-functioning posterior cruciate ligament 0 - Severe anteroposterior instability of the knee joint ● The Triathlon Tritanium Tibial Baseplates are indicated for both cemented and uncemented use. ## Summary of Technological Characteristics: The subject Triathlon components are identical in terms of intended use, indications for use, and materials and terminal sterilization methods as compared to the predicate devices. The size 0 subject components differ from the previously cleared predicate devices in terms of overall dimensions - the reduced dimensions are intended to allow the devices to be used in smaller patients. The new PS Femoral component features a reduced PS intercondylar box to allow less {8}------------------------------------------------ bone removal anteriorly. The new PSR insert is designed to offer less resistance to internal/external rotation in deep flexion in patients who can achieve this range of motion. ## Non-Clinical Testing: The following non-clinical testing was presented: - Fatigue testing of the femoral components 0 - Fatigue testing of the tibial baseplate components per ASTM F1800-12 o - Static shear testing of the insert-baseplate locking mechanism ● - o Contact area/contact stress analysis of the tibial inserts - Range of constraint of the tibial inserts - Range of motion analyses - Ethylene Oxide Sterilization Validation per EN ISO 11135:2014 Previous testing performed to characterize the Tritanium surface was reviewed, and found to be applicable to the subject Triathlon Tritanium Tibial Baseplate. The subject Triathlon components were evaluated to determine if these devices created a new worst case for image artifact, magnetically induced torque, magnetically induced displacement, and RF induced heating. These subject devices do not create a new worst case as compared to those Triathlon Total Knee components previously cleared in K172326. The subject devices are considered to be MR Conditional. Additionally, contact area/contact stress and range of motion analysis was presented to support the update in range of motion for the Triathlon system. Bacterial endotoxin testing (BET) as specified in ANSVAAMI ST72:2011 was used for pyrogenicity testing on the subject devices to achieve an Endotoxin limit of <20 EU/Device. Clinical Testing: Clinical testing was not required as a basis for substantial equivalence. Conclusion: The Triathlon® Total Knee System - Additional Components are substantially equivalent to the predicate devices identified in this premarket notification. Device comparison showed that the proposed devices are substantially equivalent in intended use, materials, and performance characteristics to the predicate devices. The proposed modifications do not affect safety or effectiveness.
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...